Home | About | RSS Feed | Contact and Publicity Guidelines | Comment Policy the Law, the Universe, and Everything 


advertise-here4


Slip Opinions


Denial of tenure case at Georgetown raises thorny issues .  LAC

NYT editorial quotes Dan Solove likening NSA snooping to Seurat art: one small dot seems trivial, but together a portrait emerges. Here. (LAC)

Warren Buffett never negotiates on price, always makes his highest offer first.  LAC

An elite decline? (kw)

Unanswered Questions (kw)

Most under-appreciated thing about Warren Buffett: he built Berkshire to last well beyond him.  (LAC, at BRK annual meeting via Motley Fool, here.)

University governance as a new topic of public discussion.

An unusual profile of Mary Anne Franks (kw)

Aggressive copyright litigation run amok. (fp)

USA Today's Matt Krantz quoting me on Warren Buffett joining Twitter.  (LAC)


Our Podcast

Subscribe to Law Talk


  • Posts by Author

  • Categories

  • Archives


  • Recent Comments


    • PrometheeFeu on Google Challenges Gag Orders Relating to Surveillance Programs, Citing First Amendment

    • AS on Unintended Consequences of Scholarship

    • JDH on The Humble Justice Scalia

    • Ken Rhodes on Grading Lessons from Cognitive Psychology

    • Ken Rhodes on Google Challenges Gag Orders Relating to Surveillance Programs, Citing First Amendment

    • Steph Tai on Grading Lessons from Cognitive Psychology

    • Neal Goldfarb on Sole Motives and University of Texas Southwestern Medical Center v. Nassar

    • Aaron Zelinsky on Grading Lessons from Cognitive Psychology

    • Brett Bellmore on Google Challenges Gag Orders Relating to Surveillance Programs, Citing First Amendment

    • Steph Tai on Grading Lessons from Cognitive Psychology

    • Aaron Zelinsky on Grading Lessons from Cognitive Psychology

    • Steph Tai on Grading Lessons from Cognitive Psychology

    • Aaron Zelinsky on Grading Lessons from Cognitive Psychology

    • Steph Tai on Grading Lessons from Cognitive Psychology

    • Charlie Naegle on Google Challenges Gag Orders Relating to Surveillance Programs, Citing First Amendment
  •  

    Site Meter

    About the Blog

    Concurring Opinions is a multiple authored, general interest legal blog.

    (Image: Wikicommons)

Beware the Superbug

posted by Frank Pasquale

If you or a relative has ever been stuck in an intensive care unit with MRSA, you know how terrible an experience that is. According to Jerome Groopman, it’s probably about to become a much more common one in the US–thanks in part to a pervasive anti-regulatory mindset and multiple failures to publicly invest in drug research the private sector will not support:

[S]tudies. . . . on how often, and for how long, antibiotics should be prescribed . . . are much easier to conduct in countries where medicine is largely socialized and prescriptions are tightly regulated. . . . In Sweden, the government closely monitors all infections, and has the power to intervene as needed. “Our infection-control people have a lot of authority,” Giske said. “This is power from the legislation.” Once a resistant microbe is identified, stringent protocols are put in place, with dramatic results. Fewer than two per cent of the staphylococci in Sweden are MRSA, compared with sixty per cent in the United States. . . .

In the past, large pharmaceutical companies were the primary sources of antibiotic research. But many of these companies have abandoned the field. . . .Drug companies are looking for blockbuster therapies that must be taken daily for decades, drugs like Lipitor, for high cholesterol, or Zyprexa, for psychiatric disorders, used by millions of people and generating many billions of dollars each year. Antibiotics are used to treat infections, and are therefore prescribed only for days or weeks. . . . [Public-private partnerships can start to fill that gap, but] “The difficulty that we are faced with is that our budget has been flat for the last five years,” [NIAID Director Anthony] Fauci told me. “In real dollars, we’ve lost almost fifteen per cent purchasing power,” because of an inflation index of about three per cent for biomedical research and development.

Won’t Grover Norquist be proud of this budget-balancing triumph?

As Kevin Outterson has written, we face a stark choice: either develop conservation strategies for existing antibiotics, or invest in inventing new ones. There is no reason to think a private sector solution can address this issue adequately–note for instance the new questions about a recently commercialized response to sepsis. Ala William James, it’s time to think of the superbug as an enemy to be battled collectively.


 August 18, 2008 at 5:54 pm   Posted in: Health Law   Print This Post Print This Post

Responses (4)

  1. Dan R. - August 18, 2008 at 6:29 pm

    Even worse for the drug companies — a new powerful antibiotic will only be rarely used. Doctors will try older drugs first, hoping to save the new one to ward off new resistances as long as possible.

  2. JP - August 18, 2008 at 7:07 pm

    A government imposed monopoly (the patent system), is a “private sector solution?”

  3. A.J. Sutter - August 18, 2008 at 10:07 pm

    Apropos of “A government imposed monopoly (the patent system), is a ‘private sector solution?’”: this is a fascinating piece of rhetoric.

    On the one hand, “government-imposed” is a typical libertarian term favoring private effort and opposed to government intervention. But libertarians usually welcome the patent system (outside software) as creating incentives for private innovation. Even Uncle Milton allowed that the patent and copyright systems were good uses of government, because they created property rights (see, e.g., _Capitalism and Freedom_ @127). The other wrinkle is “-imposed”: patents are purely voluntary, at least from the patentee’s perspective. No one forces you to get a patent. You’re free to disclose your invention and let everyone compete with you on price and marketing. Or you can keep it as a trade secret. That people get patents is a kind of revealed preference, rather than a government requirement.

    Apropos of Frank’s comment right after the block quote, is budget-balancing is really to blame? When has there been a balanced federal budget in the past 7 years? How often in the past 20?

    Still, I agree that the patent system obviously has failed to work as an incentive (not that this is exceptional). Bruce Boyden made some interesting comments to Frank’s old post that’s linked in this one. He says:

    “Don’t drug companies have an incentive to sell as many drugs as possible no matter what the patent protection is? … If you don’t have a patent, and your product is in danger of being imitated or is in fact challenged by competitors, that would seem to be the situation in which you’d want to sell the most the fastest. I suppose if there were some choice to be made — Company X can sell 100 lots now and 0 lots later, or can instead sell 50 lots now and 50 lots 10 years from now — then the length of patent exclusivity might add some amount of weight in favor of the first. But I don’t think super-bacteria present that sort of choice; they present the choice of 50 lots now (and 50 lots of some competitor’s drug now) versus 100 lots now. Given that choice, I think just about every profit-maximizing enterprise would have an incentive to opt for the latter.”

    This begs the question of whether you’d bother to invest in a product you don’t have a patent in at all. (It also begs the question of whether real-life companies are “profit-maximizing”.) Especially in the pharma industry, there are many other expensive regulatory hoops you need to jump through even to manufacture generics. Major drug companies generally choose not to develop or sell products in which they don’t have some proprietary interest.

  4. JP - August 19, 2008 at 11:42 am

    A.J.,

    My comment was purely rhetoric, and not really meant to engage with the substantive problem (which is hard, and even libertarians like me recognize that real public health issues like this may require public, rather than private, solutions).

    However, Prof. Pasquale’s tendency to blame the “free market” for every scary headline he sees is becoming reflexive and careless. There are serious arguments that innovation is stifled because of the way intellectual property rights are distributed under the design of the current patent system. Prof. Pasquale’s assumption that problem’s with the current patent system means no “private sector solution” is possible is no less a “fascinating piece of rhetoric” than my comment.

Leave a Reply

Spam protection by WP Captcha-Free


  • « Previous post
  • Next post »

Authors

Daniel J. Solove
Kaimipono Wenger
Dave Hoffman
Frank Pasquale
Deven Desai
Danielle Citron
Lawrence Cunningham
Sarah Waldeck
Jaya Ramji-Nogales
Solangel Maldonado
Gerard Magliocca

Guests

Kelli A. Alces
Andrew Blair-Stanek
Ryan Calo
Katie Eyer
Stephen Galoob
Woodrow Hartzog
Claire Hill
William McGeveran
David L. Schwartz
Babak Siavoshy
Charles K. Whitehead
Aaron Zelinsky


















Previous Guests

Michael Abramowicz
Michelle Adams
Robert Ahdieh
Marvin Ammori
Michelle Anderson
Laura Appleman
Derek Bambauer
Taunya Lovell Banks
Ann Bartow
Steven Bellovin
Adam Benforado
Gaia Bernstein
Francesca Bignami
Josh Blackman
Joseph Blocher
Jeremy Blumenthal
Kathleen Boozang
Bruce Boyden
Donald Braman
Khiara Bridges
Al Brophy
Neil H. Buchanan
Bill Burke-White
Scott Burris
Paul Butler
Ryan Calo
Naomi Cahn
Anupam Chander
Miriam Cherry
Jack Chin
Glenn Cohen
Gabriella Coleman
Jennifer Collins
Caroline Mala Corbin
Thomas Crocker
andré douglas pond cummings
Allison Danner
Laura DeNardis
Brannon Denning
Deven Desai
Mike Dimino
Mark Edwards
Maxine Eichner
Jessica Erickson
David Fagundes
Lisa Fairfax
Joshua Fairfield
Christine Haight Farley
Kim Ferzan
Dan Filler
Mary Anne Franks
Susan Freiwald
Michael Froomkin
Amanda Frost
Brian Frye
Timothy Glynn
Rachel Godsil
Eric Goldman
Kyle Graham
David Gray
Craig Green
Tristin Green
Jonathan Hafetz
Vivian E. Hamilton
Meredith Harbach
Michelle Harner
Angela Harris
Jeffrey Harrison
Hosea Harvey
Erica Hashimoto
Jennifer Hendricks
Carissa Hessick
Laura Heymann
Robert Hillman
Gilbert A. Holmes
Nicole Huberfeld
Christine Hurt
Darian Ibrahim
Sherrilyn Ifill
John Ip
Shavar Jeffries
Kevin Johnson
Kristin Johnson
Jeff Jonas
Courtney Joslin
Dan Kahan
Jeffrey Kahn
Brian Kalt
Sam Kamin
Michael Kang
Chimène Keitner
Alicia Kelly
Orin Kerr
Jay Kesten
Nancy Kim
Heidi Kitrosser
Adam Kolber
Russell Korobkin
Alex Kreit
Anita S. Krishnakumar
Susan Kuo
Greg Lastowka
Sarah Lawsky
Youngjae Lee
Margaret Lewis
Erik Lillquist
Jeff Lipshaw
Jonathan Lipson
Jacqueline Lipton
Matthew Lister
Joseph Liu
Michael Madison
Tayyab Mahmud
Kevin Noble Maillard
Solangel Maldonado
Jason Mazzone
Linda McClain
William McGeveran
Salil Mehra
Carrie Menkel-Meadow
Max Minzner
Viva Moffat
Scott Moss
Eric Muller
Janai Nelson
Jaya Ramji-Nogales
Helen Norton
Elizabeth Nowicki
Paul Ohm
Angela Onwuachi-Willing
David Opderback
David Orentlicher
Michael O'Shea
Kristen Osenga
Mary-Rose Papandrea
Rafael Pardo
Marcy Peek
Eduardo Peñalver
Robert Percival
Michael J. Pitts
Marc Poirier
David Post
Amanda Pustilnik
Shruti Rana
Geoffrey Rapp
Meredith Render
William Reynolds
Neil Richards
Lori Ringhand
Alice Ristroph
Marc Roark
Brishen Rogers
Sasha Romanosky
Aaron Saiger
Tuan Samahon
Susan Scafidi
David Schleicher
David Schraub
Paul Secunda
Lea Shaver
Jonathan Siegel
Jessica Silbey
Peter Smith
Judd Sneirson
Adam Steinman
Charles Sullivan
Rick Swedloff
Peter Swire
Olivier Sylvain
Steph Tai
Andrew Taslitz
Robert Tsai
Jenia Turner
Joseph Turow
Steve Vladeck
Ari Waldman
Spencer Weber Waller
Howard Wasserman
Melissa Waters
Elizabeth A. Wilson
Frank Wu
Alfred Yen
Corey Yung
David Zaring
Timothy Zick
Michael Zimmer
Jonathan Zittrain

Ownership

Concurring Opinions is a
general-interest legal blog
operated by Concurring
Opinions LLC, a Pennsylvania
Limited Liability Corporation.

Blogroll

Above the Law
Access to Justice
ACS Blog
Althouse
Balkinization
Becker-Posner Blog
BlackProf
BoingBoing
Chicago Law Faculty Blog
Conglomerate
CrimLaw
Crime & Federalism
CrimProf Blog
Crooked Timber
Derechoalderecho
Discourse.net
Dorf on Law
Election Law
Emergent Chaos
The Faculty Lounge
Feminist Law Profs
43(B)log
Freakonomics Blog
Freedom to Tinker
Google Blogoscoped
How Appealing
Ideoblog
Info/Law
Instapundit.com
Juris Novus
Jurisdynamics
Just Books
Law and Humanities Blog
Law and Letters
Law Librarian Blog
Legal Profession Blog
Legal Theory Blog
Legal Times Blog
Leiter Reports
Brian Leiter's Law School Reports
Lessig Blog
Madisonian Theory
Media Law Blog
Mirror of Justice
The Moderate Voice
National Security Advisors
Opinio Juris
Point of Law
PrawfsBlawg
Privacy and Security Training
ProfessorBainbridge.com
Property Prof Blog
Red Tape Chronicles
The Right Coast
Schneier on Security
SCOTUSBlog
Security Dilemmas
Sentencing Law and Policy
Simple Justice
Sivacracy.net
The Situationist
Susan Crawford
TalkLeft
Talking Points Memo
TaxProf Blog
TeachPrivacy Blog
Tech & Marketing Law
Truth on the Market
Volokh Conspiracy
WorkPlace Prof Blog
WSJ Law Blog
Wonkette
The Yin Blog


© Concurring Opinions

Powered by WordPress